Assess whether biosimilarity is analytically justified (f916a0)

Situation

An inspector asking for batch records you cannot produce this week put complete-response-letter deficiency list in front of RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT. This Pharma & Life Sciences / Pharmacovigilance close is biosimilarity is analytically justified from complete-response-letter deficiency list, and the live options are Proceed under protocol, Pause the pathway, Escalate safety review.

Decision

RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using complete-response-letter deficiency list after an inspector asking for batch records you cannot produce this week.

Hypotheses to test

• The population in complete-response-letter deficiency list is the one an inspector asking for batch records you cannot produce this week named, so Proceed under protocol follows for this Pharmacovigilance file.
• The population in complete-response-letter deficiency list is adjacent only to an inspector asking for batch records you cannot produce this week; Pause the pathway is the honest Pharma & Life Sciences call.
• An RWE group proposing a post-marketing study instead of a new RCT already contained an inspector asking for batch records you cannot produce this week before complete-response-letter deficiency list arrived; no new Pharmacovigilance path.
• Provenance on complete-response-letter deficiency list after an inspector asking for batch records you cannot produce this week is broken; do not pick Proceed under protocol or Pause the pathway yet.

Analysis required

• Check whether complete-response-letter deficiency list supports the labeled claim RWE evidence-strategy director would keep.
• Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT.
• Trace CMC, labeling, or pharmacovigilance facts in complete-response-letter deficiency list after an inspector asking for batch records you cannot produce this week.
• For this Pharma & Life Sciences Pharmacovigilance file, read complete-response-letter deficiency list against an inspector asking for batch records you cannot produce this week and write the one fact that would move biosimilarity is analytically justified for RWE evidence-strategy director.